Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Patient safety is a primary priority in the conduction of retinal gene therapy trials. An understanding of risk factors and mitigation strategies for post-procedure complications is crucial for the optimization of gene therapy clinical trial protocols. In this review, we synthesize the literature on ocular delivery methods, vector platforms, and treatment-emergent adverse effects in recent gene therapy clinical trials for inherited retinal diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Research works printed but not linked: 88
- Ong T, Pennesi ME, Birch DG, et al. Adeno-associated viral gene therapy for inherited retinal disease. Pharm Res. 2019;36:34. · DOI
- Han Z, Conley SM, Naash MI. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci. 2011;52:3051–9. · DOI · Paper page
- Kelley RA, Conley SM, Makkia R, et al. DNA nanoparticles are safe and nontoxic in non-human primate eyes. Int J Nanomed. 2018;13:1361–79. · DOI · Paper page
- Neffendorf JE, Gupta B, Williamson TH. Intraoperative complications of patients undergoing small-gauge and 20-gauge vitrectomy: a database study of 4,274 procedures. Eur J Ophthalmol. 2017;27:226–30. · doi:10.5301/ejo.5000856
- Mentens R, Stalmans P. Comparison of postoperative comfort in 20 gauge versus 23 gauge pars plana vitrectomy. Bull Soc Belge Ophtalmol. 2009;311:5–10.
- Kellner L, Wimpissinger B, Stolba U, et al. 25-gauge vs 20-gauge system for pars plana vitrectomy: a prospective randomised clinical trial. Br J Ophthalmol. 2007;91:945–8. · doi:10.1136/bjo.2006.106799
- Inoue Y, Kadonosono K, Yamakawa T, et al. Surgically-induced inflammation with 20-, 23-, and 25-gauge vitrectomy systems: an experimental study. Retina. 2009;29:477–80. · doi:10.1097/iae.0b013e31819a6004
- Nam Y, Chung H, Lee JY, et al. Comparison of 25- and 23-gauge sutureless microincision vitrectomy surgery in the treatment of various vitreoretinal diseases. Eye. 2010;24:869–74. · doi:10.1038/eye.2009.206
- Veritti D, Sarao V, Lanzetta P. A propensity-score matching comparison between 27-gauge and 25-gauge vitrectomy systems for the repair of primary rhegmatogenous retinal detachment. J Ophthalmol. 2019;2019:3120960. · DOI
- Igelman AD, Johnson JA, Taylor SC, et al. Postoperative complication rates in 23- vs 25-gauge pars plana vitrectomy. J VitreoRetin Dis. 2018;2:272–5. · doi:10.1177/2474126418785824
- Ho LY, Garretson BR, Ranchod TM, et al. Study of intraocular pressure after 23-gauge and 25-gauge pars plana vitrectomy randomized to fluid versus air fill. Retina. 2011;31:1109–17. · doi:10.1097/iae.0b013e31820b5b9b
- Charles S, Ho AC, Dugel PU, et al. Clinical comparison of 27-gauge and 23-gauge instruments on the outcomes of pars plana vitrectomy surgery for the treatment of vitreoretinal diseases. Curr Opin Ophthalmol. 2020;31:185–91. · doi:10.1097/icu.0000000000000659
- Ochakovski GA, Bartz-Schmidt KU, Fischer MD. Retinal gene therapy: surgical vector delivery in the translation to clinical trials. Front Neurosci. 2017;11:174. · DOI · Paper page
- Fan KC, Yannuzzi NA, Patel NA, et al. Surgical techniques for the subretinal delivery of pediatric gene therapy. Ophthalmol Retina. 2020;4:644–5. · DOI
- Shields RA, Ludwig CA, Powers MA, et al. Postoperative adverse events, interventions, and the utility of routine follow-up after 23-, 25-, and 27-gauge pars plana vitrectomy. Asia-Pac J Ophthalmol. 2019;8:36–42.
- Alexander P, Michaels L, Newsom R. Is day-1 postoperative review necessary after pars plana vitrectomy? Eye (London, England). 2015;29:1489–94. · doi:10.1038/eye.2015.134
- Ahn SJ, Woo SJ, Ahn J, et al. Comparison of postoperative intraocular pressure changes between 23-gauge transconjunctival sutureless vitrectomy and conventional 20-gauge vitrectomy. Eye. 2012;26:796–802. · doi:10.1038/eye.2012.23
- Kwon HJ, Kwon OW, Song WK. Semiautomated subretinal fluid injection method using viscous fluid injection mode. Retina. 2019;39:S174–S176176. · DOI
- Park JC, Ramasamy B, Shaw S, et al. A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy: incidence and risk factors. Br J Ophthalmol. 2014;98:529. · DOI
- Bhende M, Raman R, Singh N, et al. Risk factors for endophthalmitis after pars plana vitrectomies in a Tertiary Eye Institute in India. Ophthalmol Retina. 2018;2:779–84. · doi:10.1016/j.oret.2018.01.001
- Gupta OP, Maguire JI, Eagle RC Jr, et al. The competency of pars plana vitrectomy incisions: a comparative histologic and spectrophotometric analysis. Am J Ophthalmol. 2009;147(243–50):e1.
- Reibaldi M, Longo A, Reibaldi A, et al. Diathermy of leaking sclerotomies after 23-gauge transconjunctival pars plana vitrectomy: a prospective study. Retina. 2013;33:939–45. · doi:10.1097/iae.0b013e3182725d65
- Arana LA, Moreira ATR, Grandinetti AA, et al. Novel vicryl releasable suture technique to close leaking sclerotomies in a transconjunctival vitrectomy. Retina. 2019;39(Suppl 1):S108–S111111. · doi:10.1097/iae.0000000000002115
- Felfeli T, Altomare F, Mandelcorn ED. Sutureless closure of 23-and 25-gauge leaking sclerotomies with the scleral needling technique. Retina. 2020;40:838–44. · DOI
- Shimada H, Nakashizuka H, Hattori T, et al. Reduction of vitreous contamination rate after 25-gauge vitrectomy by surface irrigation with 0.25% povidone–iodine. Retina. 2013;33:143–51. · doi:10.1097/iae.0b013e318261a6ce
- Yamane S, Kadonosono K, Inoue M, et al. Effect of intravitreal gas tamponade for sutureless vitrectomy wounds: three-dimensional corneal and anterior segment optical coherence tomography study. Retina. 2011;31:702–6. · doi:10.1097/iae.0b013e3181f0d2e6
- Chiang A, Kaiser RS, Avery RL, et al. Endophthalmitis in microincision vitrectomy: outcomes of gas-filled eyes. Retina. 2011;31:1513–7. · DOI
- Chandra A, Xing W, Kadhim MR, et al. Suprachoroidal hemorrhage in pars plana vitrectomy: risk factors and outcomes over 10 years. Ophthalmology. 2014;121:311–7. · doi:10.1016/j.ophtha.2013.06.021
- Woo SJ, Park KH, Hwang J-M, et al. Risk factors associated with sclerotomy leakage and postoperative hypotony after 23-gauge transconjunctival sutureless vitrectomy. Retina. 2009;29:456–63. · DOI
- Mimouni M, Abualhasan H, Derman L, et al. Incidence and risk factors for hypotony after 25-gauge pars plana vitrectomy with nonexpansile endotamponade. Retina. 2020;40:41–6. · DOI
- Shimozono M, Oishi A, Kimakura H, et al. Three-step incision for 23-gauge vitrectomy reduces postoperative hypotony compared with an oblique incision. Ophthalmic Surg Lasers Imaging. 2011;42:20–5. · doi:10.3928/15428877-20101025-02
- Inoue M, Shinoda K, Shinoda H, et al. Two-step oblique incision during 25-gauge vitrectomy reduces incidence of postoperative hypotony. Clin Exp Ophthalmol. 2007;35:693–6. · doi:10.1111/j.1442-9071.2007.01580.x
- Barak Y, Heroman JW, Schaal S. Use of 25% sulfur hexafluoride gas mixture may minimize short-term postoperative hypotony in sutureless 25-gauge pars plana vitrectomy surgery. Clin Ophthalmol (Auckland, NZ). 2013;7:423–6.
- Ehlers JP, Dupps WJ, Kaiser PK, et al. The Prospective Intraoperative and Perioperative Ophthalmic ImagiNg with Optical CoherEncE TomogRaphy (PIONEER) study: 2-year results. Am J Ophthalmol. 2014;158:999–1007. · DOI · Paper page
- Roizenblatt M, Edwards TL, Gehlbach PL. Robot-assisted vitreoretinal surgery: current perspectives. Robot Surg (Auckland). 2018;5:1–11.
- Igarashi T, Miyake K, Asakawa N, et al. Direct comparison of administration routes for AAV8-mediated ocular gene therapy. Curr Eye Res. 2013;38:569–77. · DOI · Paper page
- Gamlin PD, Alexander JJ, Boye SL, et al. SubILM injection of AAV for gene delivery to the retina. Methods Mol Biol (Clifton, NJ). 2019;1950:249–62. · DOI · Paper page
- Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178–83. · DOI · Paper page
- Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34:S1–S18. · DOI · Paper page
- Patel SN, Gangaputra S, Sternberg P Jr, et al. Prophylaxis measures for postinjection endophthalmitis. Surv Ophthalmol. 2020;65:408–20. · DOI
- Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45:143–9. · DOI · Paper page
- Lau PE, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;2018:8567912. · DOI
- Wen JC, McCannel CA, Mochon AB, et al. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129:1551–4. · DOI
- Storey P, Dollin M, Pitcher J, et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121:283–9. · DOI · Paper page
- Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29:19–32. · DOI
- Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33:1968–70. · DOI
- Munro M, Williams GR, Ells A, et al. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections. Br J Ophthalmol. 2018;102:1254–8. · DOI
- Tustin A, Kim SJ, Chomsky A, et al. Antibacterial properties of 2% lidocaine and reduced rate of endophthalmitis after intravitreal injection. Retina. 2014;34:935–42. · doi:10.1097/iae.0000000000000014
- Storey PP, Tauqeer Z, Yonekawa Y, et al. The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab. Am J Ophthalmol. 2019;199:200–8. · DOI
- Levinson JD, Garfinkel RA, Berinstein DM, et al. Timing of povidone-iodine application to reduce the risk of endophthalmitis after intravitreal injections. Ophthalmol Retina. 2018;2:654–8. · DOI
- Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676–98. · DOI · Paper page
- Karabag RY, Parlak M, Cetin G, et al. Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports. Dig J Ophthalmol. 2015;21:8. · doi:10.5693/djo.02.2013.09.005
- Knecht PB, Michels S, Sturm V, et al. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina (Philadelphia, Pa). 2009;29:1175–81. · DOI
- Storey PP, Pancholy M, Wibbelsman TD, et al. Rhegmatogenous retinal detachment after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmology. 2019;126:1424–31. · DOI
- Yun C, Oh J, Hwang SY, et al. Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 2015;253:1465–70. · DOI
- Lemos V, Cabugueira A, Noronha M, et al. Intraocular pressure in eyes receiving intravitreal antivascular endothelial growth factor injections. Ophthalmologica. 2015;233:162–8. · DOI
- Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128:1523–7. · DOI
- Yannuzzi NA, Patel SN, Bhavsar KV, et al. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158(319–27):e2.
- Pang CE, Mrejen S, Hoang QV, et al. Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina. 2015;35:1401–6. · DOI
- Gomez J, Koozekanani DD, Feng AZ, et al. Strategies for improving patient comfort during intravitreal injections: results from a survey-based study. Ophthalmol Ther. 2016;5:183–90. · DOI
- Chen X, Seth RK, Rao VS, et al. Effects of music therapy on intravitreal injections: a randomized clinical trial. J Ocul Pharmacol Ther. 2012;28:414–9. · DOI
- Shiroma HF, Takaschima AKK, Farah ME, et al. Patient pain during intravitreal injections under topical anesthesia: a systematic review. Int J Retina Vitreous. 2017;3:23. · DOI
- Karimi S, Mosavi SA, Jadidi K, et al. Which quadrant is less painful for intravitreal injection? A prospective study. Eye. 2019;33:304–12. · DOI
- Popovic MM, Muni RH, Nichani P, et al. Topical nonsteroidal anti-inflammatory drugs for pain resulting from intravitreal injections: a meta-analysis. Ophthalmol Retina. 2020;4:461–70. · DOI
- Li Q, Miller R, Han P-Y, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760–9.
- Patel SR, Berezovsky DE, McCarey BE, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2012;53:4433–41. · DOI · Paper page
- Yiu G, Chung SH, Mollhoff IN, et al. Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates. Mol Ther Methods Clin Dev. 2020;16:179–91. · DOI · Paper page
- Yeh S, Kurup SK, Wang RC, et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). RETINA. 2019;39:1880–8. · DOI · Paper page
- Boye SE, Alexander JJ, Witherspoon CD, et al. Highly efficient delivery of adeno-associated viral vectors to the primate retina. Hum Gene Ther. 2016;27:580–97. · DOI · Paper page
- Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–60. · DOI · Paper page
- Pennesi ME, Weleber RG, Yang P, et al. Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy. Hum Gene Ther. 2018;29:1428–37. · DOI · Paper page
- Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology. 2013;120:1283–91. · DOI · Paper page
- Wang X, Yu C, Tzekov RT, et al. The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:49. · DOI · Paper page
- Dimopoulos IS, Hoang SC, Radziwon A, et al. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience. Am J Ophthalmol. 2018;193:130–42. · DOI · Paper page
- MacDonald IM, Moen C, Duncan JL, et al. Perspectives on gene therapy: choroideremia represents a challenging model for the treatment of other inherited retinal degenerations. Transl Vis Sci Technol. 2020;9:17. · DOI · Paper page
- Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology. 2003;110:1151–8. · DOI · Paper page
- Sun D, Schur RM, Sears AE, et al. Non-viral gene therapy for Stargardt disease with ECO/pRHO-ABCA4 self-assembled nanoparticles. Mol Ther. 2020;28:293–303. · DOI · Paper page
- Wilson DJ, Sahel JA, Weleber RG, et al. One year results of a phase I/IIa study of SAR422459 in patients with Stargardt macular degeneration (SMD). Investig Ophthalmol Vis Sci. 2017;58:3385.
- Talib M, van Schooneveld MJ, Thiadens AA, et al. Clinical and genetic characteristics of male patients with rpgr-associated retinal dystrophies: a long-term follow-up study. Retina. 2019;39:1186–99. · DOI · Paper page
- Wu Z, Hiriyanna S, Qian H, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet. 2015;24:3956–70. · DOI · Paper page
- Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26:354–9. · DOI · Paper page
- Michaelides M, Hunt DM, Moore AT. The cone dysfunction syndromes. Br J Ophthalmol. 2004;88:291–7. · DOI · Paper page
- Hirji N, Aboshiha J, Georgiou M, et al. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic Genet. 2018;39:149–57. · DOI · Paper page
- Yu-Wai-Man P, Griffiths PG, Brown DT, et al. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003;72:333–9. · DOI · Paper page
- Yuan J, Zhang Y, Liu H, et al. Seven-year follow-up of gene therapy for leber’s hereditary optic neuropathy. Ophthalmology. 2020;127:1125–7. · DOI · Paper page
- Pimenides D, George ND, Yates JR, et al. X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients. J Med Genet. 2005;42:e35. · DOI
- Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retinal eye Res. 2012;31:195–21212. · DOI · Paper page
- Vijayasarathy C, Sui R, Zeng Y, et al. Molecular mechanisms leading to null-protein product from retinoschisin (RS1) signal-sequence mutants in X-linked retinoschisis (XLRS) disease. Hum Mutat. 2010;31:1251–60. · DOI · Paper page
Cited by
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Such viral composition is particularly useful for diseases with large causative genes such as Stargardt disease and Usher syndrome.(22,25,26) Lentiviruses are possibly more immunogenic than AAVs.”
BackgroundLam, B. L., Pennesi, M. E., Kay, C. N., Panda, S., Gow, J. A., Zhao, G., MacLaren, R. E., MacLaren, R., Aleman, T., Birch, D., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.02.023 · Cited by 51
Therapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Advances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Metadata
- Authors
- Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H.
- Venue
- Ophthalmology and Therapy
- Published
- 2020-08-01
- Volume
- 9
- Issue
- 4
- Pages
- 709-724
- ISSN
- 2193-6528 (ISSN-L)
- 2193-8245
- OpenAlex
- W3046752007
- Cited by
- 29
- References
- 36
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Funders
- Foundation Fighting Blindness (TA-NMT-0116-0692- COLU)
- Foundation for the National Institutes of Health (P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437)
- New York State (SDHDOH01-C32590GG-3450000)
- Research to Prevent Blindness
- National Cancer Institute Core (5P30CA013696)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review. https://app.cochat.ai/papers/10.1007/s40123-020-00287-1
- The paper
- Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020). Treatment-Emergent Adverse Events in Gene Therapy Trials for Inherited Retinal Diseases: A Narrative Review. Ophthalmology and Therapy. https://doi.org/10.1007/s40123-020-00287-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.